Suvendu Giri

The paper identifies NRG1/HER3 axis activation via NE-like/EMT dedifferentiation as a mechanism of EGFR inhibitor resistance in NSCLC and shows that combining EGFR inhibition with NRG1 neutralization can eradicate tumors.

This study develops a bispecific antibody targeting MERTK and EGFR to overcome drug resistance in lung cancer with mutations in exons 19, 20, and 21.

This study identifies a p53 mutation-specific immunotherapy strategy for ovarian cancer by targeting AREG and PD-L1, showing efficacy in mouse models and patient-derived organoids.

The paper shows that inducing epithelial traits in breast cancer cells increases autophagy and DNA damage, potentially contributing to tumor dormancy and reactivation.

This study shows that TMPRSS2-ERG fusion promotes resistance to antiandrogens by interacting with GR, suggesting combined GR and AR inhibition could benefit tERG-positive prostate cancer patients.